medicated intrauterine devices

Summary

Summary: Intrauterine devices that release contraceptive agents.

Top Publications

  1. ncbi Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia
    A Kriplani
    Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
    Int J Gynaecol Obstet 97:190-4. 2007
  2. ncbi Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagia
    Julian W Barrington
    Department of Obstetrics and Gynaecology, Torbay Hospital, Torquay, Devon, UK
    Eur J Obstet Gynecol Reprod Biol 108:72-4. 2003
  3. ncbi Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia
    Robert W Shaw
    Academic Division of Obstetrics and Gynaecology, University of Nottingham, Derby, UK
    Aust N Z J Obstet Gynaecol 47:335-40. 2007
  4. ncbi Health status function after treatment with thermal balloon endometrial ablation and levonorgestrel intrauterine system for idiopathic menorrhagia: a randomized study
    Wing Hung Tam
    Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, SAR, China
    Gynecol Obstet Invest 62:84-8. 2006
  5. ncbi Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up
    Ritva Hurskainen
    Department of Obstetrics and Gynecology, University of Helsinki, Finland
    JAMA 291:1456-63. 2004
  6. ncbi Endometrial effects of intrauterine levonorgestrel
    Anja Guttinger
    Division of Reproductive and Developmental Sciences, The Queen s Medical Research Institute, Centre for Reproductive Biology, The University of Edinburgh, EH16 4TJ Edinburgh, UK
    Contraception 75:S93-8. 2007
  7. ncbi Local levonorgestrel regulation of androgen receptor and 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrium
    Kevin A Burton
    Centre for Reproductive Biology, Chancellor s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
    Hum Reprod 18:2610-7. 2003
  8. ncbi Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen
    M D Kesim
    Sisli Etfal Research and Training Hospital, 3th Obstetrics and Gynecology Clinic, Istanbul, Turkey
    Climacteric 11:252-7. 2008
  9. ncbi Update on treatment of menstrual disorders
    David H Eizenberg
    Med J Aust 179:454-5; author reply 455. 2003
  10. ncbi Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu 375 during post-marketing monitoring in New Zealand
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    N Z Med J 116:U538. 2003

Research Grants

Detail Information

Publications164 found, 100 shown here

  1. ncbi Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia
    A Kriplani
    Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
    Int J Gynaecol Obstet 97:190-4. 2007
    ..To evaluate the efficacy, acceptability, and possible side effects of a levonorgestrel-releasing intrauterine system for menorrhagia...
  2. ncbi Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagia
    Julian W Barrington
    Department of Obstetrics and Gynaecology, Torbay Hospital, Torquay, Devon, UK
    Eur J Obstet Gynecol Reprod Biol 108:72-4. 2003
    ..To compare the effectiveness of endometrial thermal ablation and the levonorgestrel intrauterine system (LNG-IUS) in the management of menorrhagia...
  3. ncbi Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia
    Robert W Shaw
    Academic Division of Obstetrics and Gynaecology, University of Nottingham, Derby, UK
    Aust N Z J Obstet Gynaecol 47:335-40. 2007
    ....
  4. ncbi Health status function after treatment with thermal balloon endometrial ablation and levonorgestrel intrauterine system for idiopathic menorrhagia: a randomized study
    Wing Hung Tam
    Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, SAR, China
    Gynecol Obstet Invest 62:84-8. 2006
    ..To compare patients' health status function after treatment with thermal balloon endometrial ablation (TBEA) and levonorgestrel intrauterine system (LNG-IUS) for idiopathic menorrhagia...
  5. ncbi Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up
    Ritva Hurskainen
    Department of Obstetrics and Gynecology, University of Helsinki, Finland
    JAMA 291:1456-63. 2004
    ..Both the levonorgestrel-releasing intrauterine system (LNG-IUS) and hysterectomy have proven effective for treatment of menorrhagia but there are no long-term comparative studies measuring cost and quality of life...
  6. ncbi Endometrial effects of intrauterine levonorgestrel
    Anja Guttinger
    Division of Reproductive and Developmental Sciences, The Queen s Medical Research Institute, Centre for Reproductive Biology, The University of Edinburgh, EH16 4TJ Edinburgh, UK
    Contraception 75:S93-8. 2007
    ..Much remains to be determined about the mechanisms involved in suppression of menstruation, BTB episodes and the local endometrial environment with local LNG administration...
  7. ncbi Local levonorgestrel regulation of androgen receptor and 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrium
    Kevin A Burton
    Centre for Reproductive Biology, Chancellor s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
    Hum Reprod 18:2610-7. 2003
    ....
  8. ncbi Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen
    M D Kesim
    Sisli Etfal Research and Training Hospital, 3th Obstetrics and Gynecology Clinic, Istanbul, Turkey
    Climacteric 11:252-7. 2008
    ..To investigate the long-term effects of a levonorgestrel-releasing intrauterine system on the endometrium and lipid profile of breast cancer patients taking tamoxifen...
  9. ncbi Update on treatment of menstrual disorders
    David H Eizenberg
    Med J Aust 179:454-5; author reply 455. 2003
  10. ncbi Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu 375 during post-marketing monitoring in New Zealand
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    N Z Med J 116:U538. 2003
    ..To compare the incidence of reported insertion problems with the levonorgestrel-releasing intrauterine device (Mirena) with that of the copper device Multiload Cu 375...
  11. ncbi Re: The use of levonorgestrel-releasing intrauterine system for the treatment of menorrhagia in women with inherited bleeding disorders
    Rebecca Curtis
    BJOG 113:248-9. 2006
  12. ncbi The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometrium
    B A Roopa
    Department of Obstetrics and Gynaecology, National University Hospital, National University of Singapore, Singapore
    Hum Reprod 18:1809-19. 2003
    ....
  13. ncbi Use of the levonorgestrel-IUD in the treatment of menorrhagia: improving patient outcomes while reducing the need for surgical management
    Andrew M Kaunitz
    Department of Obstetrics and Gynecology, University of Florida Health Science Center, Jacksonville, Florida, USA
    Manag Care Interface 20:47-50. 2007
    ..In particular, the levonorgestrel-releasing intrauterine system (LNG-IUS), a nonsurgical, reversible treatment, provides effective management for many women with menorrhagia while minimizing morbidity and health care costs...
  14. ncbi The effect of the levonorgestrel intrauterine system on uterine artery blood flow 1 year after insertion
    A Haberal
    Department of Gynecology, S S K Ankara Maternity and Women s Health Teaching Hospital, Ankara, Turkey
    Ultrasound Obstet Gynecol 27:316-9. 2006
    ..To assess whether the morphological alterations of the endometrium induced by the levonorgestrel intrauterine system affect the uterine artery vasculature...
  15. ncbi The Mirena levonorgestrel system
    C Jay McGavigan
    Department of Obstetrics and Gynecology, Southern General Hospital, South Glasgow University Hospitals NHS Trust, Govan, Glasgow, UK
    Drugs Today (Barc) 39:973-84. 2003
    ..Detailed counseling is crucial to explain this anticipated side effect in order to reduce unnecessary discontinuation of treatment...
  16. ncbi Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers
    T Kucuk
    Department of Obstetrics and Gynecology, GATA School of Medicine, Ankara, Turkey
    Clin Exp Obstet Gynecol 35:57-60. 2008
    ..To compare the efficacy of three progestin regimens in perimenopausal menorrhagia...
  17. ncbi Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system
    Dirk Wildemeersch
    Contrel Research, Technology Park 3, 9052 Zwijnaarde, Ghent, Belgium
    Contraception 71:470-3. 2005
    ..The daily release of the LNG IUS was approximately 20 mug...
  18. ncbi Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging
    Aristides M Bragheto
    Human Reproduction Unit, Department of Obstetrics and Gynecology, Campinas, 13084 971 SP, Brazil
    Contraception 76:195-9. 2007
    ..This study was conducted to evaluate the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on adenomyotic lesions diagnosed and monitored by magnetic resonance imaging (MRI)...
  19. ncbi Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts
    Peter C Reid
    Luton and Dunstable NHS Trust, Luton, UK
    BJOG 112:1121-5. 2005
    ..To compare the efficacy and tolerability of the levonorgestrel intrauterine system (LNG IUS) with mefenamic acid in the management of objective idiopathic menorrhagia...
  20. ncbi The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders
    May Wahab
    BJOG 112:1455-6. 2005
  21. ncbi The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders
    C E C Kingman
    Department of Obstetrics and Gynaecology, Royal Free Hospital, London, UK
    BJOG 111:1425-8. 2004
    ..The levonorgestrel-releasing intrauterine system (LNG-IUS) is used commonly by gynaecologists as a contraceptive and to treat menorrhagia. However, its efficacy has not been examined in women with inherited bleeding disorders...
  22. ncbi Levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding
    Ritva Hurskainen
    Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, PL 140, 0029 HUS, Helsinki, Finland
    Curr Opin Obstet Gynecol 16:487-90. 2004
    ..The levonorgestrel-releasing intrauterine system is an effective medical treatment for menorrhagia. Emerging clinical and research evidence suggests that this new treatment modality has major health benefits...
  23. ncbi Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis
    Moamar Al-Jefout
    Department of Obstetrics and Gynaecology, Queen Elizabeth II Research Institute for Mothers and Infants, University of Sydney, New South Wales, Australia
    Aust N Z J Obstet Gynaecol 47:247-9. 2007
    ....
  24. ncbi Modern management of abnormal uterine bleeding: the levonorgestrel intra-uterine system
    Diana Mansour
    Graingerville Clinic, Newcastle General Hospital, Newcastle upon Tyne, UK
    Best Pract Res Clin Obstet Gynaecol 21:1007-21. 2007
    ..This article will outline the development of the IUS, highlighting the most important recent areas of research covering its use to control menstrual blood loss and pain...
  25. ncbi Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia
    Xiujuan Qi
    Department of Obstetrics and Gynecology, Qingdao University Medical School, Qingdao, PR China
    Gynecol Obstet Invest 65:266-8. 2008
    ..Histological morphology of endometrial samples after 6 months' exposure to LNG-IUS showed secretory or atrophic glands with decidualized stroma. Two healthy babies were born following ovulation induction after removal of the LNG-IUS...
  26. ncbi Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas
    Takeshi Maruo
    Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, 650 0017, Japan
    Contraception 75:S99-103. 2007
    ..The cell type-specific action of CDB2914 on leiomyoma cells, without affecting the surrounding normal myometrial cells, is meaningful for understanding the usefulness of CDB2914 in the medical treatment of uterine myomas...
  27. ncbi Levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of essential menorrhagia: predictors of outcome
    Ritva Hurskainen
    Departments of Obstetrics and Gynecology, University Hospitals of Helsinki, Finland
    Acta Obstet Gynecol Scand 83:401-3. 2004
    ..However, the treatment with LNG-IUS seemed to be an appropriate alternative to hysterectomy for all women who perceived their MBL heavy...
  28. ncbi Menorrhagia, mechanisms and targeted therapies
    Julia Osei
    Reproductive and Developmental Sciences Obstetrics and Gynaecology, Centre for Reproductive Biology, University of Edinburgh, Edinburgh, UK
    Curr Opin Obstet Gynecol 17:411-8. 2005
    ..This review summarizes recent developments in the nonsurgical approach to treating menorrhagia...
  29. ncbi A retrospective cohort study comparing microwave endometrial ablation with levonorgestrel-releasing intrauterine device in the management of heavy menstrual bleeding
    Richard Henshaw
    South East Regional Health Service, Adelaide, South Australia, Australia
    Aust N Z J Obstet Gynaecol 42:205-9. 2002
    ..To compare microwave endometrial ablation (MEA) with a levonorgestrel-releasing intrauterine device (Mirena) in the management of heavy menstrual bleeding...
  30. ncbi Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women
    Päivi Lehtovirta
    Department of Obstetrics and Gynecology, University of Helsinki, SF 00029 Helsinki, Finland
    Contraception 75:37-9. 2007
    ..Yet, little is known about LNG-IUS use in HIV-infected women...
  31. ncbi Progestin-releasing intrauterine systems
    T Luukkainen
    Steroid Research Laboratory, Institute of Biomedicine, University of Helsinki, Helsinki, Finland
    Semin Reprod Med 19:355-63. 2001
    ..Users should be told that the LNG IUS does not prevent sexually transmitted infection, and therefore women at risk should also use condoms for their protection...
  32. ncbi Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study
    D Wildemeersch
    Contrel Research, Technology Park Zwijnaarde, Ghent, Belgium
    Contraception 66:93-9. 2002
    ....
  33. ncbi The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis
    Ana Carolina Japur de Sa Rosa E Silva
    Department of Obstetrics and Gynecology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil
    Fertil Steril 86:742-4. 2006
    ..The levonorgestrel-releasing intrauterine device was found to be as efficient as GnRH agonist in reducing CA-125 serum levels...
  34. ncbi Levonorgestrel intrauterine system: bleeding disorders and anticoagulant therapy
    Rezan A Kadir
    Department of Obstetrics and Gynaecology and Katharine Dormandy Haemophilia Center and Haemostasis Unit, Royal Free Hospital, NW3 2QG London, UK
    Contraception 75:S123-9. 2007
    ..Proper counselling remains crucial for patients' satisfaction...
  35. ncbi [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil]
    Daniela Angerame Yela
    Departamento de Obstetricia e Ginecologia, Faculdade de Medicina, Universidade Estadual de Campinas UNICAMP, Campinas, Brazil
    Rev Assoc Med Bras 52:32-6. 2006
    ....
  36. ncbi The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in women
    Naomi B Morison
    Prince Henry s Institute, PO Box 5152, Clayton, Victoria, Australia
    Reproduction 133:309-21. 2007
    ..MMP7 was primarily associated with tissue repair. Therefore, this model mimics some of the changes observed in endometria of women using p-only contraceptives and provides an opportunity for functional studies...
  37. ncbi The local progestational effect of the levonorgestrel-releasing intrauterine system: a sonographic and Doppler flow study
    Y Zalel
    Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel
    Hum Reprod 17:2878-80. 2002
    ..We aimed to evaluate the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on the uterine vasculature and the endometrium...
  38. pmc The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology
    V Phillips
    Department of Pathology, Royal Group of Hospitals Trust, Grosvenor Road, Belfast BT12 6BL, Northern Ireland, UK
    J Clin Pathol 56:305-7. 2003
    ..The Mirena coil is a levonorgestrel releasing intrauterine device that is in widespread use. This study aims to document the endometrial morphology associated with this device...
  39. ncbi A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding
    R A Busfield
    Department of Obstetrics and Gynaecology, National Women s Hospital, University of Auckland, Auckland, New Zealand
    BJOG 113:257-63. 2006
    ..To compare the levonorgestrel intrauterine system (LNG-IUS) (Mirena); Schering Co., Turku, Finland) and thermal balloon ablation (Thermachoice; Gynecare Inc., Menlo Park, CA, USA) for the treatment of heavy menstrual bleeding...
  40. ncbi The effect of hysterectomy or levonorgestrel-releasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trial
    K Halmesmäki
    Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
    BJOG 114:563-8. 2007
    ..To compare among women with menorrhagia the effect of hysterectomy or levonorgestrel-releasing intrauterine system (LNG-IUS) on sexual functioning...
  41. ncbi Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study
    Erika Baldaszti
    Ludwig Boltzmann Institute for Womens Health Research, A 1180, Vienna, Bastiengasse 36 38, Austria
    Contraception 67:87-91. 2003
    ..LNG-IUS is a well-accepted contraceptive method, without negative influences on the sexual relationship between users and their partners, and is suitable for women requiring long-term reversible contraceptive protection...
  42. ncbi Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas
    Jarbas Magalhães
    Department of Obstetrics and Gynecology, Clinic of Gynecological Endocrinology, School of Medicine, Santa Casa de Sao Paulo, São Paulo 01221 900, Brazil
    Contraception 75:193-8. 2007
    ..A control group used the device as a contraceptive method (n=28)...
  43. ncbi Revisiting the intrauterine contraceptive device in adolescents
    Alina Toma
    Department of Obstetrics and Gynaecology, Queen s University, Kingston, Ontario, Canada
    J Pediatr Adolesc Gynecol 19:291-6. 2006
    ....
  44. ncbi Medical and surgical management of adenomyosis
    Cynthia Farquhar
    Department of Obstetrics and Gynaecology, National Womens Health at Auckland, City Hospital, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Best Pract Res Clin Obstet Gynaecol 20:603-16. 2006
    ..Hysterectomy or use of the levonorgestrel intrauterine system (LNG-IUS) remains the mainstay of treatment...
  45. pmc Hormonal contraception and risk of venous thromboembolism: national follow-up study
    Øjvind Lidegaard
    Gynaecological Clinic, Rigshospitalet, Copenhagen University, DK 2100 Copenhagen, Denmark
    BMJ 339:b2890. 2009
    ..To assess the risk of venous thrombosis in current users of different types of hormonal contraception, focusing on regimen, oestrogen dose, type of progestogen, and route of administration...
  46. ncbi Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants
    Irving Sivin
    Population Council, Center for Biomedical Research, New York, New York 10021, USA
    Drug Saf 26:303-35. 2003
    ..and pelvic inflammatory disease are reduced in comparison with those of women using copper or non-medicated intrauterine devices. Risks of developing gallbladder disease and hypertension or borderline hypertension, although small, ..
  47. ncbi Neoplasia with use of intrauterine devices
    Kathryn M Curtis
    Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
    Contraception 75:S60-9. 2007
    ..Additionally, hormone-releasing IUDs or intrauterine systems (IUSs) release progestins or progesterone into the uterus. Both of these mechanisms may affect users' risk for neoplasia...
  48. ncbi Advances in uterine protein research: reproduction and cancer
    M Seppala
    Department of Obstetrics and Gynecology, Clinical Chemistry, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    Int J Gynaecol Obstet 85:105-18. 2004
    ..Research on functional glycomics continues to produce significant information on fundamental aspects of fertilization, implantation, pregnancy and cancer...
  49. ncbi The levonorgestrel-releasing intrauterine system in modern gynaecology
    C Jay McGavigan
    Department of Gynaecology, Glasgow Royal Infirmary, Glasgow G4 0SF
    Br J Hosp Med (Lond) 66:574-7. 2005
    ..Compliance can sometimes be hampered by troublesome side effects (principally breakthrough bleeding) but appropriate counselling can reduce unnecessary discontinuation...
  50. ncbi Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview
    Rajesh Varma
    Academic Department of Obstetrics and Gynaecology, Birmingham Women s Hospital, Birmingham B15 2TG, UK
    Eur J Obstet Gynecol Reprod Biol 125:9-28. 2006
    ..This systematic enquiry and overview evaluates the quality of evidence relating to the non-contraceptive therapeutic uses of LNG-IUS in gynaecology...
  51. ncbi Long-term use of the levonorgestrel-releasing intrauterine system
    Pirjo Inki
    Bayer Schering Pharma AG, D 13342 Berlin, Germany
    Contraception 75:S161-6. 2007
    ..g., oral progestins). Use of the LNG IUS in combination with estrogen therapy in women undergoing menopausal transition seems to be well tolerated and associated with a favorable bleeding pattern...
  52. ncbi Levonorgestrel-releasing intrauterine system vs. transcervical endometrial resection for dysfunctional uterine bleeding
    B Gupta
    Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
    Int J Gynaecol Obstet 95:261-6. 2006
    ..To compare the acceptability, efficacy, adverse effects, and user satisfaction of a levonorgestrel intrauterine system (LNG-IUS) and transcervical resection of the endometrium (TCRE) for the treatment of dysfunctional uterine bleeding...
  53. ncbi Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms--a review
    Yoav Peled
    Helen Schneider Women s Hospital, Rabin Medical Center, Beilinston Campus, Petah Tiqwa, Israel
    Menopause 14:550-4. 2007
    ..In this article we review the findings on the use of the novel levonorgestrel-releasing intrauterine system as a therapeutic tool for localized, rather than systemic, progesterone administration in postmenopausal women...
  54. ncbi Pseudo-decidual reaction to Mirena coil in a cervical smear: a potential diagnostic pitfall for false-positive cervical cytology
    C Hughes
    Cytopathology 16:268-9. 2005
  55. ncbi The intrauterine device: rethinking old paradigms
    Katherine W Morgan
    University of Utah College of Nursing, 10 South 2000 East, Salt Lake City, UT 84112, USA
    J Midwifery Womens Health 51:464-70. 2006
    ..In light of this data, the IUD should be made available to women at low-risk for sexually-transmitted infections and should not be denied to women on the basis of parity or marital status...
  56. ncbi Five years' experience with a small intracervical/intrauterine levonorgestrel-releasing device
    Paivi Pakarinen
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, 00029 HUS Helsinki, Finland
    Contraception 72:342-5. 2005
    ..A randomized study was performed to compare the efficacy, safety and acceptability of a new model of an intracervical/intrauterine contraceptive device (ICD) releasing 20 microg of levonorgestrel (LNG) per day...
  57. ncbi [Levonorgestrel-releasing intrauterine system for treatment of dysmenorrhea associated with adenomyosis]
    Jie Sheng
    Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China
    Zhonghua Fu Chan Ke Za Zhi 41:467-70. 2006
    ..To evaluate the efficacy and safety of a levonorgestrel-releasing intrauterine system (LNG-IUS) for the treatment of dysmenorrhea associated with adenomyosis...
  58. ncbi Primary ovarian pregnancy with a levonorgestrel intrauterine system
    Emmanuel Kalu
    Assisted Conception Unit, St Helier Hospital, Carshalton, UK
    J Fam Plann Reprod Health Care 32:253-4. 2006
  59. ncbi Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian Survey
    Sidsel Graff-Iversen
    National Health Screening Service, Oslo, Norway
    Contraception 66:7-13. 2002
    ..Use of the IUD with levonorgestrel was also linked with a decreased risk of high serum triglycerides and of high non-HDL-cholesterol concentrations and a total/HDL-cholesterol ratio similar to that of nonusers of hormones...
  60. ncbi Exacerbation of Crohn's disease after insertion of a levonorgestrel intrauterine system: a case report
    Jacqueline Wakeman
    Langton Medical Group, St Chad Health Centre, Lichfield, UK
    J Fam Plann Reprod Health Care 29:154. 2003
    ....
  61. ncbi Levonorgestrel-releasing intrauterine system and new-onset acne
    Jordan R Ilse
    Cutis 82:158. 2008
  62. ncbi Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis
    J B Laoag-Fernandez
    Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan
    Hum Reprod 18:694-9. 2003
    ..Endometrial angiogenesis is believed to be regulated by angiogenic factors. The study aim was to evaluate the effects of LNg-IUS on vascular endothelial growth factor (VEGF) and adrenomedullin (AM) expression in the endometrium...
  63. ncbi Levonorgestrel intrauterine system: a first-line medical treatment for heavy menstrual bleeding
    Anita L Nelson
    David Geffen School of Medicine at UCLA, Torrance, CA, USA
    Womens Health (Lond Engl) 6:347-56. 2010
    ....
  64. ncbi Ectopic pregnancy risk when contraception fails. A review
    Lesley Anne Furlong
    U S Food and Drug Administration, HFD 580, 5600 Fishers Lane, Rockville, MD 20857, USA
    J Reprod Med 47:881-5. 2002
    ..To alert clinicians to the risk of ectopic pregnancy when certain contraceptive methods fail by summarizing data from trials reviewed by the U.S. Food and Drug Administration (FDA)...
  65. ncbi Can the levonorgestrel intrauterine system replace surgical treatment for the management of menorrhagia?
    Rani Nagrani
    Department of Obstetrics and Gynaecology, Singleton Hospital, Swansea, UK
    BJOG 109:345-7. 2002
    ..4% avoided surgery. The LNG-IUS is well accepted and effective in the management of menorrhagia and has major cost implications to the National Health Service...
  66. ncbi Ectopic pregnancy with a translocated Mirena intrauterine system
    Fook Ng Kee Kwong
    Leicester Royal Infirmary NHS Trust, Leicester, UK
    J Fam Plann Reprod Health Care 28:95-6. 2002
    ..The IUS was removed laparoscopically. This is likely to be the first reported case of a simultaneous ectopic pregnancy and an extrauterine system. It is not clear whether removal of the Mirena IUS was necessary...
  67. ncbi Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue
    Rodrigo Alves Ferreira
    Department of Obstetrics and Gynecology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto, SP, 14049 900, Brazil
    Contraception 81:117-22. 2010
    ....
  68. ncbi Fertility and endocrine effects of intra-abdominally misplaced intrauterine system for more than 2 years: a case report and review of the literature
    George Botros
    Countess of Chester, O and G, Chester, UK
    Hum Fertil (Camb) 12:119-21. 2009
    ..Intraabdominal misplacement of the LNG-IUS has been reported in the literature with variable consequences and effects. In this case report, we reviewed the literature and assessed the fertility and endocrine consequences...
  69. ncbi [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)]
    F Imperato
    II Facolta di Medicina e Chirurgia, Istituto di Ostetricia e Ginecologia, Universita degli Studi La Sapienza, Rome, Italy
    Minerva Ginecol 54:271-8. 2002
    ..The authors evaluated the effect of copper surface area on uterine bleeding...
  70. ncbi Pregnancy during the use of levonorgestrel intrauterine system
    Tiina Backman
    Department of Obstetrics and Gynecology, University Hospital of Turku, Finland
    Am J Obstet Gynecol 190:50-4. 2004
    ..This study was undertaken to evaluate the pregnancy rate with the levonorgestrel intrauterine system (LNG IUS) and to analyze the outcome of pregnancies with the LNG IUS in situ in regular use...
  71. ncbi The levonorgestrel intrauterine system (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction
    I Lete
    Santiago Apostol Hospital, Vitoria, Alava, Spain
    Eur J Contracept Reprod Health Care 13:231-7. 2008
    ..To evaluate patient satisfaction and improvement in quality of life (QoL) among women with idiopathic menorrhagia treated with the levonorgestrel intrauterine system (LNG-IUS)...
  72. ncbi Cervical cytological studies in women inserted with Norplant-I contraceptive
    Jata S Misra
    Human Reproduction Research Centre, Department of Obstetrics and Gynaecology, C S M Medical University, Lucknow, India
    Diagn Cytopathol 29:136-9. 2003
    ..The accumulated data indicate the safety of long-term use of Norplants upto 5 yr, as far as oncogenic potential is concerned...
  73. ncbi [Extrauterine pregnancy with gestagen-releasing intrauterine device in situ]
    Mette Schou Mikkelsen
    Regionshospitalet Randers, gynaekologisk obstetrisk afdeling, Denmark
    Ugeskr Laeger 172:1304-5. 2010
    ..We describe one of these rare cases of ectopic pregnancy in a woman aged 37 years, who was admitted to hospital with abdominal pain and vaginal bleeding...
  74. ncbi Viable cervical pregnancy with levonorgestrel containing intrauterine device, treated successfully with methotrexate and mifepristone
    Ingrid De Greef
    Eur J Obstet Gynecol Reprod Biol 120:233-5. 2005
  75. ncbi Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrel
    R Hurskainen
    Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, PO Box 140, Helsinki, Finland
    Mol Hum Reprod 6:1013-8. 2000
    ..No significant differences were found in the parameters studied between the women with and without breakthrough bleeding 6 months after insertion of an LNG-IUS...
  76. ncbi Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Contraception 81:481-6. 2010
    ..Misoprostol has been studied intensively to produce cervical dilatation. To date, no studies have evaluated the effectiveness, safety or acceptability of this treatment for repeat intrauterine device insertions...
  77. ncbi The future of hysterectomy
    Ray Garry
    University of Western Australia, King Edward Memorial Hospital, Subiaco, Western Australia, Australia
    BJOG 112:133-9. 2005
  78. ncbi Differential elevation of matrix metalloproteinase expression in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time
    Soraya Labied
    Groupe Interdisciplinaire de Génoprotéomique Appliquée GIGA R, Laboratory of Tumor and Development Biology, Centre de Recherche en cancérologie Expérimentale, University of Liege, Tour de Pathologie B23, Sart Tilman, B 4000 Liege, Belgium
    Hum Reprod 24:113-21. 2009
    ..Thus the objective of this study was to compare matrix metalloproteinase (MMP) expression in endometrium during luteal phase and in short-term (1 month) and long-term (> or =6 months) LNG-IUS users...
  79. ncbi The levonorgestrel-releasing intrauterine system: an updated review of the contraceptive and noncontraceptive uses
    Camaryn Chrisman
    Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Clin Obstet Gynecol 50:886-97. 2007
    ..In addition to its contraceptive effect, the levonorgestrel intrauterine system offers potential therapeutic benefits in other clinical contexts, including menorrhagia, symptomatic fibroids, endometriosis, and endometrial suppression...
  80. ncbi Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders
    Andrea S Lukes
    Carolina Women s Research and Wellness Center, Chapel Hill, North Carolina 27514, USA
    Fertil Steril 90:673-7. 2008
    ..To evaluate the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) in women with known hemostatic disorders and abnormal uterine bleeding...
  81. ncbi Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine system
    Alessandra Peloggia
    Human Reproduction Unit, Department of Obstetrics and Gynaecology, School of Medicine, Universidade Estadual de Campinas UNICAMP, Campinas, SP, Brazil
    Hum Reprod 21:1129-34. 2006
    ..The objective was to assess endometrial chemokines in users of the levonorgestrel-releasing intrauterine system (LNG-IUS) and correlate them with leucocyte populations, uterine natural killer cells (uNK) and mast cells (MCs)...
  82. ncbi The effect of the levonorgestrel-releasing intrauterine system and the copper intrauterine device on subendometrial microvascularization and uterine artery blood flow
    Mirela Foresti Jiménez
    Faculdade de Medicina, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil
    Fertil Steril 90:1574-8. 2008
    ..To evaluate the effect of the levonorgestrel intrauterine system (LNG-IUS) and TCU 380A on the subendometrial vascularization and the uterine artery blood flow during the midluteal phase...
  83. pmc Safety of a progesterone-releasing intravaginal device as assessed from vaginal mucosal integrity and indicators of systemic inflammation in postpartum dairy cows
    Robert B Walsh
    Department of Population Medicine, University of Guelph, Guelph, Ontario N1G 2W1
    Can J Vet Res 72:43-9. 2008
    ..There was no significant difference in the circulating haptoglobin concentration between the 3 groups of cows. Culture revealed commensal bacterial growth in the vagina of all the cows...
  84. ncbi A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms
    K Halmesmäki
    Department of Obstetrics and Gynecology, Central Hospital of Päijät Häme, Keskussairaalankatu 7, 15850 Lahti, Finland
    Hum Reprod 19:378-82. 2004
    ..The purpose of this study was to compare the effects of hysterectomy and a levonorgestrel-releasing intrauterine system (LNG-IUS) on serum FSH levels and menopausal symptoms...
  85. ncbi Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population
    Laure Morin-Papunen
    Department of Obstetrics and Gynecology, University Hospital of Oulu, Oulu, Finland
    Am J Obstet Gynecol 199:529.e1-529.e10. 2008
    ..We compared the metabolic and cardiovascular parameters of a reference group of women with those of women who used 2 contraceptive regimes that are used worldwide: the levonorgestrel-releasing intrauterine device and oral contraceptives...
  86. ncbi [A levonorgestrel-containing IUD for the treatment of endometriosis]
    E Stekkinger
    Deventer Ziekenhuis, Afd Gynaecologie, Verloskunde en Voortplantings geneeskunde, Postbus 5001, 7400 GC Deventer
    Ned Tijdschr Geneeskd 151:2372-6. 2007
    ..However, the level of evidence of these studies is lower than that of the standard hormonal treatment options, since large randomised controlled trials are still lacking...
  87. ncbi The use of levonorgestrel - IUD in the treatment of uterine myoma in Thai women
    Kanok Jindabanjerd
    Department of Obstetric and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
    J Med Assoc Thai 89:S147-51. 2006
    ..This study was designed to evaluate the potential usefulness of the levonorgestrel-releasing intrauterine device (LNG - IUD ; Mirena) in treating women with uterine myomas...
  88. ncbi Effect of different contraceptive methods on the oxidative stress status in women aged 40 48 years from the ELAN study in the province of Liege, Belgium
    J Pincemail
    Department of Cardiovascular Surgery, University of Liege, CHU Sart Tilman, 4000 Liege, Belgium
    Hum Reprod 22:2335-43. 2007
    ..Among conditions known to influence oxidative stress, the use of oral contraception (OC) in women has been a matter of ongoing discussion...
  89. ncbi Uterine ultrasonographic changes during endometriosis treatment: a comparison between levonorgestrel-releasing intrauterine devices and a gonadotropin-releasing hormone agonist
    Luiz Alberto Manetta
    Department of Gynecology and Obstetrics, Faculty of Medicine Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil
    Ultrasound Med Biol 34:1914-8. 2008
    ..In conclusion, levonorgestrel released directly onto the endometrium by the LNG-IUD induced smaller uterine changes than did the hypoestrogenism induced by GnRHa. Nevertheless, both promoted similar effects on endometrial thickness...
  90. ncbi The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women
    Peter Vestergaard
    Department of Endocrinology and Metabolism C, Aarhus Amtssygehus, DK 8000 Aarhus, Denmark
    Contraception 78:459-64. 2008
    ..Depot medroxyprogesterone acetate (DMPA) use may be associated with an increased risk of fractures; however, nothing is known about the risk associated with intrauterine contraceptive device (IUD) use...
  91. ncbi Use of the Levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users
    Husnu Gorgen
    Department of Obstetrics and Gynecology, Haseki Education and Research Hospital, Istanbul, Turkey
    Arch Gynecol Obstet 279:835-40. 2009
    ..The aim of the present study was to measure the treatment of menorrhagia and health-related quality of life (QoL) in Levonorgestrel-releasing intrauterine system (LNG-IUS) in Turkish women...
  92. ncbi The Femilis LNG-IUS: contraceptive performance-an interim analysis
    Dirk Wildemeersch
    Outpatient Gynaecological Clinic and Training Centre, Ghent, Belgium
    Eur J Contracept Reprod Health Care 14:103-10. 2009
    ..To provide an update on the experience with the Femilis levonorgestrel-releasing intrauterine system (LNG-IUS) used for up to five years by parous and nulliparous women, particularly with regard to its contraceptive performance...
  93. ncbi A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well
    Heli K Lyytinen
    Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, HUS, Finland
    Int J Cancer 126:483-9. 2010
    ..15; 1.72-2.68) was also associated with an increased risk. The association between HT use and the risk for breast cancer shows a large variation between various forms of HT, and also the use of LNG-IUS may carry a risk...
  94. ncbi The levonorgestrel intrauterine system in nulliparous women
    Sarah Prager
    Department of Obstetrics, Gynecology and Reproductive Sciences, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Contraception 75:S12-5. 2007
    ..In conclusion, LNG-IUS is both safe and extremely efficacious for use in nulliparous women...
  95. ncbi The levonorgestrel-releasing intrauterine system and endometriosis staging
    Mariana Kefalás Oliveira Gomes
    Department of Gynecology and Obstetrics, University of São Paulo at Ribeirão Preto School of Medicine, Ribeirao Preto, Brazil
    Fertil Steril 87:1231-4. 2007
    ..Both treatments reduced the extent of pelvic endometriotic lesions in patients with chronic pelvic pain...
  96. ncbi Lost levonorgestrel IUD: diagnosis and therapy
    Shmuel Nitke
    Soroka University Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel
    Contraception 69:289-93. 2004
    ..Lost levonorgestrel-releasing IUDs might be found in the mid-upper abdomen, embedded in omentum tissue, and this area should be explored first during laparoscopy...
  97. ncbi Clinical practice. Long-acting methods of contraception
    Herbert B Peterson
    Department of Maternal and Child Health, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, USA
    N Engl J Med 353:2169-75. 2005
  98. ncbi Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs
    Walli Bounds
    Department of Obstetrics and Gynaecology, University College London and Research Co ordinator, Margaret Pyke Centre, London, UK
    J Fam Plann Reprod Health Care 28:78-80. 2002
    ..Contraception for women on enzyme-inducing drugs...
  99. ncbi New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation
    R Sitruk-Ware
    Center for Biomedical Research, Population Council and Rockefeller University, New York, NY 10021, USA
    Climacteric 10:358-70. 2007
    ..Several of these systems are either available or in development. Long-term studies on the risk/benefit of various non-oral formulations are certainly warranted...
  100. ncbi Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia
    Anne Beate Vereide
    Department of Gynecology and Obstetrics, Institute of Clinical Medicine, Norway
    Gynecol Oncol 101:214-23. 2006
    ..The effect on progesterone and estrogen receptor expression in glands and stroma after two different treatment regimens of endometrial hyperplasia was determined...
  101. ncbi A comparison of oral misoprostol tablets and vaginal prostaglandin E2 pessary in induction of labour at term
    Anjum Ara Hassan
    Department of Obstetrics and Gynaecology, Hamdard University Hospital, Karachi
    J Coll Physicians Surg Pak 15:284-7. 2005
    ..To compare the cost-effectiveness, mode of delivery, fetal and maternal outcome of oral Misoprostol and vaginal prostaglandin E2 pessary in induction of labour at term...

Research Grants6

  1. VULVODYNIA PREVALENCE AND EFFICACY OF 4 INTERVENTIONS
    Gloria Bachmann; Fiscal Year: 2004
    ..Our ultimate goal is to share findings from this and related research with the broadest cross-spectrum of women that we can. ..
  2. PDE3 Inhibitors: Selective Blockers of Oocyte Maturation
    Jeffrey Jensen; Fiscal Year: 2007
    ..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
  3. Clinical Research in Human Fertility
    Joseph Stanford; Fiscal Year: 2005
    ..Standford to develop his skills and gain the expertise needed to accomplish his goals. ..
  4. Control of menstrual bleeding disturbances in women
    Ian Fraser; Fiscal Year: 2006
    ..This study aims to explore these possibilities in large scale clinical studies, scientific study of vascular and molecular changes in endometrium and with the exploration of molecular mechanisms in mice. ..
  5. DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
    David Archer; Fiscal Year: 2006
    ..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..